Researchers report the ability to improve safety and efficacy using a CRISPR-Cas9 variant known as miCas9.
Using a new variant to repair DNA will improve both safety and effectiveness of the much-touted CRISPR-Cas9 tool in genetic research, Michigan Medicine researchers say.
Those two key problems – safety and efficacy – are what continue to hold CRISPR-Cas9 gene targeting back from its full clinical potential, explains co-senior author Y. Eugene Chen, M.D., Ph.D., a professor of internal medicine, cardiac surgery, physiology, pharmacology and medicinal chemistry, from the Michigan Medicine Frankel Cardiovascular Center.
The new CRISPR-Cas9 variant improves efficiency when inserting a gene or DNA fragment to a precise location in the genome, known as knocking in. It also reduces the rate of unintended insertions or deletions, known as indels, of base pairs that often happen while gene editing.
“We name it meticulous integration Cas9, or miCas9, to reflect its extraordinary capacity to enable maximum integration, yet with minimal indels, as well as to recognize its development at the University of Michigan,” write senior authors Chen, Jifeng Zhang and Jie Xu for Nature’s “Behind the Paper” series. “It provides a ‘one small stone for three birds’ tool in gene editing.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
MiCas9
- Feed has no items.
Go deeper with Google Headlines on:
MiCas9
Go deeper with Bing News on:
CRISPR-Cas9
- Genetic Screening Technique Kills Off Parasite Inside Host Cell
Further, although CRISPR/Cas9-based screens have assigned roles to some Toxoplasma genes, the functions of encoded proteins have proven difficult to assign. To overcome this problem, we devised a ...
- CRISPR Therapeutics (CRSP) – Analysts’ Weekly Ratings Updates
A number of research firms have changed their ratings and price targets for CRISPR Therapeutics (NASDAQ: CRSP): 5/11/2022 – CRISPR Therapeutics had its price target lowered by analysts at Oppenheimer ...
- Scribe Pursues CRISPR Therapies with Expanded Biogen Collaboration
Founder, President and CEO Benjamin L. Oakes, PhD discusses the Biogen collaboration, and his company’s progress in developing its genome editing technology, in an exclusive interview with GEN Edge.
- CRISPR Therapeutics AG (NASDAQ:CRSP) Forecasted to Post Q2 2022 Earnings of ($2.37) Per Share
Stock analysts at Jefferies Financial Group cut their Q2 2022 earnings per share estimates for CRISPR Therapeutics in a research report issued to clients and investors on Tuesday, May 10th. Jefferies ...
- Novel supramolecular CRISPR-Cas9 carrier enables more efficient genome editing
CRISPR-Cas9 is considered a revolutionary gene editing tool, but its applications are limited by a lack of methods by which it can be safely and efficiently delivered into cells. Recently ...